The Clinical Observation And Experimental Study Of Method Of Liangxuesanyu And Yiqizhixue In Chronic Idiopathic Thrombocytopenic Purpura

Objective:1.To observe clinical efficacy of Liangxuesanyu and Yiqi-zhixue therapy combine with glucorticoid in chronic idiopathic thrombo-cytopenic purpura (CITP).2.To study treatment mechanism of Liangxuesanyu and Yiqizhixue therapy in chronic idiopathic thrombocytopenic purpura.Methods:43cases of the same baseline level CITP patients were divided into treatment group (Ningxue pill combined with glucocorticoid) and control group (conventional glucocorticoid therapy) randomly, during three months coures.Analysis of the clinical efficacy,colony forming unit-megakaryoeyte and expression rate of platelet surface glycoprotein of change.Results:1.Western medicine and TCM clinical efficacy were86.36%vs.71.43%and90.91%vs.76.19%after treatment,so the treatment group was superior to control group(P<0.05).2.TCM syndrome integral of treatment group is lower than the control group(P<0.05) after treatment.3.Platelet count of treatment group is superior to control group(P<0.05) during the glucocorticoid reduction course;elevated platelet significantly and peak time of treatment group was4days in advance than control group.4.PAIgM and PAIgG of treatment group is lower than control group (P<0.05).5.Granular and thronbocytogenous megakaryocyte of treatment group is better than control group (P<0.05).6.During the treatment,adverse events in treatment group is lower than in control group (P<0.05).7.CFU-MK and total colony counts of treatment group is better than control group (P<0.05) after treatment.8.In treatment group,the expression rate of CD41and CD61was better than in control group (P<0.05).Conclusion:1.Liangxuesanyu and Yiqizhixue therapy combine with glucorticoid in CITP can enhance the clinical efficacy,obtain stable efficacy and at the same time can reduce the side effects of glucocorticoids also.2.Liangxuesanyu and Yiqizhixue therapy can increase colony forming unit-megakaryoeyte and expression rate of platelet surface glycoprotein.3.PAIg can not only combine with platelet surface glycoprotein,but also may be associate with megakaryocyte progenitor cell and megakaryocyte,affecting quantity and quality of platelet formation in every stage.4.Liangxuesanyu and Yiqizhixue therapy can promote the megakaryocyte maturation and differentiation;promote platelet production and release;reduce destruction of megakaryocyte progenitor cells, megakaryocytes and platelets in various stages, resulting in hematopoietic cells, progenitor cells, functional cell multistage exerts its therapeutic effect on CITP.